Porphyria cutanea tarda: Effects and risk factors for hepatotoxicity from high-dose chloroquine treatment

Acta Dermato-Venereologica

Volumn 87, Issue 5, 2007, Pages 401-405

  Rossmann Ringdahl, Ingrid ^a   Olsson, Rolf ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chloroquine; Haemochromatosis; Hepatitis C; Phlebotomy; Porphyria cutanea tarda

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; CHLOROQUINE; FERRITIN; UROPORPHYRIN; ANTIMALARIAL AGENT; PORPHYRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOCHROMATOSIS; HUMAN; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; LIVER DISEASE; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; URINE;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIMALARIALS; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; PORPHYRINS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TRANSAMINASES;

EID: 38449107512     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0260     Document Type: Article

References (20)

1. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976; 58: 1089-1097.
2. Lundvall O. Phlebotomy treatment of porphyria cutanea tarda. Acta Derm Venereol Suppl 1982; 100: 107-118.
3. Taljaard JJ, Shanley BC, Stewart-Wynne EG, Deppe WM, Joubert SM. Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol 1972; 87: 261-269.
4. Kordac V, Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol 1974; 90: 95-100.
5. Seubert S, Seubert A, Stella AM, Guzman H, Batlle A. [Results of treatment of porphyria cutanea tarda with bloodletting and chloroquine]. Z Hautkr 1990; 65: 223-225.
6. Kostler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005; 6: 377-383.
7. Malina L. Treatment of chronic hepatic porphyria (PCT). Photodermatol 1986; 3: 113-121.
8. Swanbeck G, Wennersten G. Treatment of porphyria cutanea tarda with chloroquine and phlebotomy. Br J Dermatol 1977; 97: 77-81.
9. Malkinson FD, Levitt L. Hydroxychloroquine treatment of porphyria cutanea tarda. Arch Dermatol 1980; 116: 1147-1150.
10. Wennersten G, Ros AM. Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy. Acta Derm Venereol Suppl 1982; 100: 119-123.
11. Petersen CS, Thomsen K. High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol 1992; 26: 614-619.
12. Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 2005; 85: 337-341.
13. Vogler WR, Galambos JT, Olansky S. Biochemical effects of chloroquine therapy in porphyria cutanea tarda. Am J Med 1970; 49: 316-321.
14. Stricker BHC, editor. Drug-induced hepatic injury, 2nd edn. Amsterdam; New York: Elsevier, 1992.
15. Scholnick PL, Epstein J, Marver HS. The molecular basis of the action of chloroquine in porphyria cutanea tarda. J Invest Dermatol 1973; 61: 226-232.
16. Goerz G, Bolsen K, Merk H. Influence of chloroquine on the porphyrin metabolism. Arch Dermatol Res 1985; 277: 114-117.
17. Vizethum W, Bolsen K, Simon K, Weber K, Goerz G. [Influence of chloroquine on the hexachlorobenzene-induced porphyria. Investigations in the skin, liver, and urine]. Arch Dermatol Res 1980; 267: 123-130.
18. Stolzel U, Kostler E, Schuppan D, Richter M, Wollina U, Doss MO, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139: 309-313.
19. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-2113.
20. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68: 525-533.